Y155H amino acid substitution in influenza A(H1N1)pdm09 viruses does not confer a phenotype of reduced susceptibility to neuraminidase inhibitors.
Identifieur interne : 000200 ( Main/Exploration ); précédent : 000199; suivant : 000201Y155H amino acid substitution in influenza A(H1N1)pdm09 viruses does not confer a phenotype of reduced susceptibility to neuraminidase inhibitors.
Auteurs : U. Perez-Sautu [Espagne] ; F. Pozo ; I. Cuesta ; S. Monzon ; A. Calderon ; M. Gonzalez ; M. Molinero ; I. Lopez-Miragaya ; S. Rey ; A. Ca Izares ; G. Rodriguez ; C. Gonzalez-Velasco ; A. Lackenby ; I. CasasSource :
- Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin [ 1560-7917 ] ; 2014.
Descripteurs français
- KwdFr :
- ARN viral (génétique), Analyse de séquence d'ADN (MeSH), Antienzymes (pharmacologie), Antienzymes (usage thérapeutique), Antiviraux (pharmacologie), Antiviraux (usage thérapeutique), Espagne (épidémiologie), Femelle (MeSH), Grippe humaine (traitement médicamenteux), Grippe humaine (virologie), Grippe humaine (épidémiologie), Humains (MeSH), Mâle (MeSH), Oséltamivir (pharmacologie), Oséltamivir (usage thérapeutique), Pandémies (MeSH), Phénotype (MeSH), Protéines virales (MeSH), Résistance virale aux médicaments (génétique), Saisons (MeSH), Sialidase (génétique), Sous-type H1N1 du virus de la grippe A (classification), Sous-type H1N1 du virus de la grippe A (effets des médicaments et des substances chimiques), Sous-type H1N1 du virus de la grippe A (génétique), Sous-type H1N1 du virus de la grippe A (isolement et purification), Substitution d'acide aminé (génétique), Techniques immunoenzymatiques (MeSH), Tests de sensibilité microbienne (MeSH), Zanamivir (pharmacologie), Zanamivir (usage thérapeutique).
- MESH :
- effets des médicaments et des substances chimiques : Sous-type H1N1 du virus de la grippe A.
- génétique : ARN viral, Résistance virale aux médicaments, Sialidase, Sous-type H1N1 du virus de la grippe A, Substitution d'acide aminé.
- isolement et purification : Sous-type H1N1 du virus de la grippe A.
- pharmacologie : Antienzymes, Antiviraux, Oséltamivir, Zanamivir.
- traitement médicamenteux : Grippe humaine.
- usage thérapeutique : Antienzymes, Antiviraux, Oséltamivir, Zanamivir.
- virologie : Grippe humaine.
- épidémiologie : Espagne, Grippe humaine.
- Analyse de séquence d'ADN, Femelle, Humains, Mâle, Pandémies, Phénotype, Protéines virales, Saisons, Techniques immunoenzymatiques, Tests de sensibilité microbienne.
- Wicri :
- geographic : Espagne.
English descriptors
- KwdEn :
- Amino Acid Substitution (genetics), Antiviral Agents (pharmacology), Antiviral Agents (therapeutic use), Drug Resistance, Viral (genetics), Enzyme Inhibitors (pharmacology), Enzyme Inhibitors (therapeutic use), Female (MeSH), Humans (MeSH), Immunoenzyme Techniques (MeSH), Influenza A Virus, H1N1 Subtype (classification), Influenza A Virus, H1N1 Subtype (drug effects), Influenza A Virus, H1N1 Subtype (genetics), Influenza A Virus, H1N1 Subtype (isolation & purification), Influenza, Human (drug therapy), Influenza, Human (epidemiology), Influenza, Human (virology), Male (MeSH), Microbial Sensitivity Tests (MeSH), Neuraminidase (genetics), Oseltamivir (pharmacology), Oseltamivir (therapeutic use), Pandemics (MeSH), Phenotype (MeSH), RNA, Viral (genetics), Seasons (MeSH), Sequence Analysis, DNA (MeSH), Spain (epidemiology), Viral Proteins (MeSH), Zanamivir (pharmacology), Zanamivir (therapeutic use).
- MESH :
- chemical , genetics : Neuraminidase, RNA, Viral.
- chemical , pharmacology : Antiviral Agents, Enzyme Inhibitors, Oseltamivir, Zanamivir.
- geographic , epidemiology : Spain.
- classification : Influenza A Virus, H1N1 Subtype.
- drug effects : Influenza A Virus, H1N1 Subtype.
- drug therapy : Influenza, Human.
- epidemiology : Influenza, Human.
- genetics : Amino Acid Substitution, Drug Resistance, Viral, Influenza A Virus, H1N1 Subtype.
- isolation & purification : Influenza A Virus, H1N1 Subtype.
- chemical , therapeutic use : Antiviral Agents, Enzyme Inhibitors, Oseltamivir, Zanamivir.
- virology : Influenza, Human.
- Female, Humans, Immunoenzyme Techniques, Male, Microbial Sensitivity Tests, Pandemics, Phenotype, Seasons, Sequence Analysis, DNA, Viral Proteins.
Abstract
The Y155H amino acid substitution in the neuraminidase gene (NA) has previously been associated with highly reduced inhibition by neuraminidase inhibitors in the seasonal H1N1 influenza A virus which circulated in humans before the 2009 pandemic. During the 2012/13 epidemic season in Spain, two A(H1N1) pdm09 viruses bearing the specific Y155H substitution in the NA were detected and isolated from two patients diagnosed with severe respiratory syndrome and pneumonia requiring admission to the intensive care unit. Contrary to what was observed in the seasonal A(H1N1) viruses, neither of the Y155H A(H1N1) pdm09 viruses described here showed a phenotype of reduced inhibition by NAIs as determined by the neuraminidase enzyme inhibition assay (MUNANA). High-throughput sequencing of the NA of both Y155H viruses showed that they were composed to >99% of H155 variants. We believe that this report can contribute to a better understanding of the biological significance of amino acid substitutions in the neuraminidase protein with regard to susceptibility of influenza viruses to neuraminidase inhibitors. This is of critical importance for optimal management of influenza disease patients.
PubMed: 25033052
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Y155H amino acid substitution in influenza A(H1N1)pdm09 viruses does not confer a phenotype of reduced susceptibility to neuraminidase inhibitors.</title><author><name sortKey="Perez Sautu, U" sort="Perez Sautu, U" uniqKey="Perez Sautu U" first="U" last="Perez-Sautu">U. Perez-Sautu</name><affiliation wicri:level="3"><nlm:affiliation>National Influenza Centre of Madrid, National Centre for Microbiology, Carlos III Health Institute, Majadahonda, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>National Influenza Centre of Madrid, National Centre for Microbiology, Carlos III Health Institute, Majadahonda, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Pozo, F" sort="Pozo, F" uniqKey="Pozo F" first="F" last="Pozo">F. Pozo</name></author><author><name sortKey="Cuesta, I" sort="Cuesta, I" uniqKey="Cuesta I" first="I" last="Cuesta">I. Cuesta</name></author><author><name sortKey="Monzon, S" sort="Monzon, S" uniqKey="Monzon S" first="S" last="Monzon">S. Monzon</name></author><author><name sortKey="Calderon, A" sort="Calderon, A" uniqKey="Calderon A" first="A" last="Calderon">A. Calderon</name></author><author><name sortKey="Gonzalez, M" sort="Gonzalez, M" uniqKey="Gonzalez M" first="M" last="Gonzalez">M. Gonzalez</name></author><author><name sortKey="Molinero, M" sort="Molinero, M" uniqKey="Molinero M" first="M" last="Molinero">M. Molinero</name></author><author><name sortKey="Lopez Miragaya, I" sort="Lopez Miragaya, I" uniqKey="Lopez Miragaya I" first="I" last="Lopez-Miragaya">I. Lopez-Miragaya</name></author><author><name sortKey="Rey, S" sort="Rey, S" uniqKey="Rey S" first="S" last="Rey">S. Rey</name></author><author><name sortKey="Ca Izares, A" sort="Ca Izares, A" uniqKey="Ca Izares A" first="A" last="Ca Izares">A. Ca Izares</name></author><author><name sortKey="Rodriguez, G" sort="Rodriguez, G" uniqKey="Rodriguez G" first="G" last="Rodriguez">G. Rodriguez</name></author><author><name sortKey="Gonzalez Velasco, C" sort="Gonzalez Velasco, C" uniqKey="Gonzalez Velasco C" first="C" last="Gonzalez-Velasco">C. Gonzalez-Velasco</name></author><author><name sortKey="Lackenby, A" sort="Lackenby, A" uniqKey="Lackenby A" first="A" last="Lackenby">A. Lackenby</name></author><author><name sortKey="Casas, I" sort="Casas, I" uniqKey="Casas I" first="I" last="Casas">I. Casas</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25033052</idno><idno type="pmid">25033052</idno><idno type="wicri:Area/Main/Corpus">00202</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">00202</idno><idno type="wicri:Area/Main/Curation">000202</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000202</idno><idno type="wicri:Area/Main/Exploration">000202</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Y155H amino acid substitution in influenza A(H1N1)pdm09 viruses does not confer a phenotype of reduced susceptibility to neuraminidase inhibitors.</title><author><name sortKey="Perez Sautu, U" sort="Perez Sautu, U" uniqKey="Perez Sautu U" first="U" last="Perez-Sautu">U. Perez-Sautu</name><affiliation wicri:level="3"><nlm:affiliation>National Influenza Centre of Madrid, National Centre for Microbiology, Carlos III Health Institute, Majadahonda, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>National Influenza Centre of Madrid, National Centre for Microbiology, Carlos III Health Institute, Majadahonda, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Pozo, F" sort="Pozo, F" uniqKey="Pozo F" first="F" last="Pozo">F. Pozo</name></author><author><name sortKey="Cuesta, I" sort="Cuesta, I" uniqKey="Cuesta I" first="I" last="Cuesta">I. Cuesta</name></author><author><name sortKey="Monzon, S" sort="Monzon, S" uniqKey="Monzon S" first="S" last="Monzon">S. Monzon</name></author><author><name sortKey="Calderon, A" sort="Calderon, A" uniqKey="Calderon A" first="A" last="Calderon">A. Calderon</name></author><author><name sortKey="Gonzalez, M" sort="Gonzalez, M" uniqKey="Gonzalez M" first="M" last="Gonzalez">M. Gonzalez</name></author><author><name sortKey="Molinero, M" sort="Molinero, M" uniqKey="Molinero M" first="M" last="Molinero">M. Molinero</name></author><author><name sortKey="Lopez Miragaya, I" sort="Lopez Miragaya, I" uniqKey="Lopez Miragaya I" first="I" last="Lopez-Miragaya">I. Lopez-Miragaya</name></author><author><name sortKey="Rey, S" sort="Rey, S" uniqKey="Rey S" first="S" last="Rey">S. Rey</name></author><author><name sortKey="Ca Izares, A" sort="Ca Izares, A" uniqKey="Ca Izares A" first="A" last="Ca Izares">A. Ca Izares</name></author><author><name sortKey="Rodriguez, G" sort="Rodriguez, G" uniqKey="Rodriguez G" first="G" last="Rodriguez">G. Rodriguez</name></author><author><name sortKey="Gonzalez Velasco, C" sort="Gonzalez Velasco, C" uniqKey="Gonzalez Velasco C" first="C" last="Gonzalez-Velasco">C. Gonzalez-Velasco</name></author><author><name sortKey="Lackenby, A" sort="Lackenby, A" uniqKey="Lackenby A" first="A" last="Lackenby">A. Lackenby</name></author><author><name sortKey="Casas, I" sort="Casas, I" uniqKey="Casas I" first="I" last="Casas">I. Casas</name></author></analytic><series><title level="j">Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin</title><idno type="eISSN">1560-7917</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amino Acid Substitution (genetics)</term><term>Antiviral Agents (pharmacology)</term><term>Antiviral Agents (therapeutic use)</term><term>Drug Resistance, Viral (genetics)</term><term>Enzyme Inhibitors (pharmacology)</term><term>Enzyme Inhibitors (therapeutic use)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Immunoenzyme Techniques (MeSH)</term><term>Influenza A Virus, H1N1 Subtype (classification)</term><term>Influenza A Virus, H1N1 Subtype (drug effects)</term><term>Influenza A Virus, H1N1 Subtype (genetics)</term><term>Influenza A Virus, H1N1 Subtype (isolation & purification)</term><term>Influenza, Human (drug therapy)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (virology)</term><term>Male (MeSH)</term><term>Microbial Sensitivity Tests (MeSH)</term><term>Neuraminidase (genetics)</term><term>Oseltamivir (pharmacology)</term><term>Oseltamivir (therapeutic use)</term><term>Pandemics (MeSH)</term><term>Phenotype (MeSH)</term><term>RNA, Viral (genetics)</term><term>Seasons (MeSH)</term><term>Sequence Analysis, DNA (MeSH)</term><term>Spain (epidemiology)</term><term>Viral Proteins (MeSH)</term><term>Zanamivir (pharmacology)</term><term>Zanamivir (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>ARN viral (génétique)</term><term>Analyse de séquence d'ADN (MeSH)</term><term>Antienzymes (pharmacologie)</term><term>Antienzymes (usage thérapeutique)</term><term>Antiviraux (pharmacologie)</term><term>Antiviraux (usage thérapeutique)</term><term>Espagne (épidémiologie)</term><term>Femelle (MeSH)</term><term>Grippe humaine (traitement médicamenteux)</term><term>Grippe humaine (virologie)</term><term>Grippe humaine (épidémiologie)</term><term>Humains (MeSH)</term><term>Mâle (MeSH)</term><term>Oséltamivir (pharmacologie)</term><term>Oséltamivir (usage thérapeutique)</term><term>Pandémies (MeSH)</term><term>Phénotype (MeSH)</term><term>Protéines virales (MeSH)</term><term>Résistance virale aux médicaments (génétique)</term><term>Saisons (MeSH)</term><term>Sialidase (génétique)</term><term>Sous-type H1N1 du virus de la grippe A (classification)</term><term>Sous-type H1N1 du virus de la grippe A (effets des médicaments et des substances chimiques)</term><term>Sous-type H1N1 du virus de la grippe A (génétique)</term><term>Sous-type H1N1 du virus de la grippe A (isolement et purification)</term><term>Substitution d'acide aminé (génétique)</term><term>Techniques immunoenzymatiques (MeSH)</term><term>Tests de sensibilité microbienne (MeSH)</term><term>Zanamivir (pharmacologie)</term><term>Zanamivir (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Neuraminidase</term><term>RNA, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term><term>Enzyme Inhibitors</term><term>Oseltamivir</term><term>Zanamivir</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Spain</term></keywords><keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Amino Acid Substitution</term><term>Drug Resistance, Viral</term><term>Influenza A Virus, H1N1 Subtype</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>ARN viral</term><term>Résistance virale aux médicaments</term><term>Sialidase</term><term>Sous-type H1N1 du virus de la grippe A</term><term>Substitution d'acide aminé</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antienzymes</term><term>Antiviraux</term><term>Oséltamivir</term><term>Zanamivir</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Enzyme Inhibitors</term><term>Oseltamivir</term><term>Zanamivir</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antienzymes</term><term>Antiviraux</term><term>Oséltamivir</term><term>Zanamivir</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Espagne</term><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Female</term><term>Humans</term><term>Immunoenzyme Techniques</term><term>Male</term><term>Microbial Sensitivity Tests</term><term>Pandemics</term><term>Phenotype</term><term>Seasons</term><term>Sequence Analysis, DNA</term><term>Viral Proteins</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Analyse de séquence d'ADN</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Pandémies</term><term>Phénotype</term><term>Protéines virales</term><term>Saisons</term><term>Techniques immunoenzymatiques</term><term>Tests de sensibilité microbienne</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Espagne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The Y155H amino acid substitution in the neuraminidase gene (NA) has previously been associated with highly reduced inhibition by neuraminidase inhibitors in the seasonal H1N1 influenza A virus which circulated in humans before the 2009 pandemic. During the 2012/13 epidemic season in Spain, two A(H1N1) pdm09 viruses bearing the specific Y155H substitution in the NA were detected and isolated from two patients diagnosed with severe respiratory syndrome and pneumonia requiring admission to the intensive care unit. Contrary to what was observed in the seasonal A(H1N1) viruses, neither of the Y155H A(H1N1) pdm09 viruses described here showed a phenotype of reduced inhibition by NAIs as determined by the neuraminidase enzyme inhibition assay (MUNANA). High-throughput sequencing of the NA of both Y155H viruses showed that they were composed to >99% of H155 variants. We believe that this report can contribute to a better understanding of the biological significance of amino acid substitutions in the neuraminidase protein with regard to susceptibility of influenza viruses to neuraminidase inhibitors. This is of critical importance for optimal management of influenza disease patients.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25033052</PMID><DateCompleted><Year>2014</Year><Month>09</Month><Day>02</Day></DateCompleted><DateRevised><Year>2014</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1560-7917</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>27</Issue><PubDate><Year>2014</Year><Month>Jul</Month><Day>10</Day></PubDate></JournalIssue><Title>Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin</Title><ISOAbbreviation>Euro Surveill.</ISOAbbreviation></Journal><ArticleTitle>Y155H amino acid substitution in influenza A(H1N1)pdm09 viruses does not confer a phenotype of reduced susceptibility to neuraminidase inhibitors.</ArticleTitle><Pagination><MedlinePgn>14-20</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">20849</ELocationID><Abstract><AbstractText>The Y155H amino acid substitution in the neuraminidase gene (NA) has previously been associated with highly reduced inhibition by neuraminidase inhibitors in the seasonal H1N1 influenza A virus which circulated in humans before the 2009 pandemic. During the 2012/13 epidemic season in Spain, two A(H1N1) pdm09 viruses bearing the specific Y155H substitution in the NA were detected and isolated from two patients diagnosed with severe respiratory syndrome and pneumonia requiring admission to the intensive care unit. Contrary to what was observed in the seasonal A(H1N1) viruses, neither of the Y155H A(H1N1) pdm09 viruses described here showed a phenotype of reduced inhibition by NAIs as determined by the neuraminidase enzyme inhibition assay (MUNANA). High-throughput sequencing of the NA of both Y155H viruses showed that they were composed to >99% of H155 variants. We believe that this report can contribute to a better understanding of the biological significance of amino acid substitutions in the neuraminidase protein with regard to susceptibility of influenza viruses to neuraminidase inhibitors. This is of critical importance for optimal management of influenza disease patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Perez-Sautu</LastName><ForeName>U</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>National Influenza Centre of Madrid, National Centre for Microbiology, Carlos III Health Institute, Majadahonda, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pozo</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Cuesta</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Monzon</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Calderon</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Molinero</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lopez-Miragaya</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Rey</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Cañizares</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Gonzalez-Velasco</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Lackenby</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Casas</LastName><ForeName>I</ForeName><Initials>I</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>07</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Sweden</Country><MedlineTA>Euro Surveill</MedlineTA><NlmUniqueID>100887452</NlmUniqueID><ISSNLinking>1025-496X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>20O93L6F9H</RegistryNumber><NameOfSubstance UI="D053139">Oseltamivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber><NameOfSubstance UI="C487630">NA protein, influenza A virus</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber><NameOfSubstance UI="D009439">Neuraminidase</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6O3XI777I</RegistryNumber><NameOfSubstance UI="D053243">Zanamivir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007124" MajorTopicYN="N">Immunoenzyme Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009439" MajorTopicYN="N">Neuraminidase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053139" MajorTopicYN="N">Oseltamivir</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012621" MajorTopicYN="N">Seasons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017422" MajorTopicYN="N">Sequence Analysis, DNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053243" MajorTopicYN="N">Zanamivir</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25033052</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Espagne</li></country><region><li>Communauté de Madrid</li></region><settlement><li>Madrid</li></settlement></list><tree><noCountry><name sortKey="Ca Izares, A" sort="Ca Izares, A" uniqKey="Ca Izares A" first="A" last="Ca Izares">A. Ca Izares</name><name sortKey="Calderon, A" sort="Calderon, A" uniqKey="Calderon A" first="A" last="Calderon">A. Calderon</name><name sortKey="Casas, I" sort="Casas, I" uniqKey="Casas I" first="I" last="Casas">I. Casas</name><name sortKey="Cuesta, I" sort="Cuesta, I" uniqKey="Cuesta I" first="I" last="Cuesta">I. Cuesta</name><name sortKey="Gonzalez Velasco, C" sort="Gonzalez Velasco, C" uniqKey="Gonzalez Velasco C" first="C" last="Gonzalez-Velasco">C. Gonzalez-Velasco</name><name sortKey="Gonzalez, M" sort="Gonzalez, M" uniqKey="Gonzalez M" first="M" last="Gonzalez">M. Gonzalez</name><name sortKey="Lackenby, A" sort="Lackenby, A" uniqKey="Lackenby A" first="A" last="Lackenby">A. Lackenby</name><name sortKey="Lopez Miragaya, I" sort="Lopez Miragaya, I" uniqKey="Lopez Miragaya I" first="I" last="Lopez-Miragaya">I. Lopez-Miragaya</name><name sortKey="Molinero, M" sort="Molinero, M" uniqKey="Molinero M" first="M" last="Molinero">M. Molinero</name><name sortKey="Monzon, S" sort="Monzon, S" uniqKey="Monzon S" first="S" last="Monzon">S. Monzon</name><name sortKey="Pozo, F" sort="Pozo, F" uniqKey="Pozo F" first="F" last="Pozo">F. Pozo</name><name sortKey="Rey, S" sort="Rey, S" uniqKey="Rey S" first="S" last="Rey">S. Rey</name><name sortKey="Rodriguez, G" sort="Rodriguez, G" uniqKey="Rodriguez G" first="G" last="Rodriguez">G. Rodriguez</name></noCountry><country name="Espagne"><region name="Communauté de Madrid"><name sortKey="Perez Sautu, U" sort="Perez Sautu, U" uniqKey="Perez Sautu U" first="U" last="Perez-Sautu">U. Perez-Sautu</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeEspagneV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000200 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000200 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeEspagneV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:25033052
|texte= Y155H amino acid substitution in influenza A(H1N1)pdm09 viruses does not confer a phenotype of reduced susceptibility to neuraminidase inhibitors.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25033052" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeEspagneV1
| This area was generated with Dilib version V0.6.37. |  |